Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide
Status:
Completed
Trial end date:
2019-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to adjust the amount of docetaxel participants receive based on
the level of docetaxel measured in their blood. This method of dose adjustment is called
pharmacokinetic (PK)-adjusted docetaxel. The researchers believe that adjusting the dose of
docetaxel using this method will lessen the side effects associated with docetaxel in cancer
treatment.
Phase:
Phase 4
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute